awmsg logo



fampridine (Fampyra®)


Reference No. 349

Publication date:
25/09/2014


Last review date:
13/12/2017

Appraisal information

fampridine (Fampyra®) 10 mg prolonged-release tablet


Company: Biogen Idec Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 23/07/2014
AWMSG meeting date: 03/09/2014
   
   
Submission Type: Directed
Status: Not recommended
Advice No: 2714
Ratification by Welsh Government: 24/09/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Fampridine (Fampyra®) is not recommended for use within NHS Wales for the improvement of walking in adult patients with multiple sclerosis with walking disability (Expanded Disability Status Scale [EDSS] 4-7). The case for cost-effectiveness has not been proven.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download